CB1-cannabinoid-, TRPV1-vanilloid- and NMDA-glutamatergic-receptor-signalling systems interact in the prelimbic cerebral cortex to control neuropathic pain symptoms

• Published in: Brain research bulletin Vol. 165; pp. 118 - 128
• Main Authors: Medeiros, Priscila, Oliveira-Silva, Mariana, Negrini-Ferrari, Sylmara Esther, Medeiros, Ana Carolina, Elias-Filho, Daoud Hibraim, Coimbra, Norberto Cysne, de Freitas, Renato Leonardo
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.12.2020
• Subjects: Chronic pain; Endocannabinoid CB1receptors; Mechanical allodynia; NMDA glutamatergic receptors; Peripheral neuropathy; Prelimbic medial prefrontal cortex; TRPV1 endovanilloid receptors; NP; CNS; LTP; LY235959; Peripheral neuropathy; MDC; MDL; PNS; AM251; IASP; NMDA; AEA; CETEA; Endocannabinoid CB1receptors; 6-I-CPS; Prelimbic medial prefrontal cortex; COBEA; CCI; CL; MWT; PrL; TRPV1; Chronic pain; mPFC; CB1; PC; VM; NMDA glutamatergic receptors; TRPV1 endovanilloid receptors; BDA; OLDA; Mechanical allodynia
• ISSN: 0361-9230; 1873-2747
• DOI: 10.1016/j.brainresbull.2020.09.013

[Display omitted] •PrL cortex is connected to dorsal thalamus nuclei related to pain control.•PrL cortex potentiated mechanical allodynia by NMDA and TRPV1 receptor activation.•Attenuation of allodynia depends on CB1 receptor activation in PrL cortex during NP.•AEA reduces mechanical allodynia by recruiting PrL CB1 endocannabinoid receptors.•AEA increased mechanical allodynia by recruiting PrL TRPV1 endovanilloid receptors. Neuropathic pain (NP) is a challenge due to our limited understanding of the mechanisms that initiate and maintain chronic pain. The prelimbic division (PrL) of the medial prefrontal cortex (mPFC) is an important area of the emotional and cognitive components of pain and pharmacological systems can interact into the neocortex to elaborate the chronic pain. This work aimed to investigate the pharmacological cross-talk between synaptic neurotransmission, neuroanatomical approaches and NP conditions. A bidirectional neural tract tracer, the 3000-molecular-weight biodextran (BDA) was microinjected into the PrL cortex. The mechanical withdrawal threshold (MWT) was recorded by a von Frey test, and the effect of prelimbic cortex CB1, NMDA, and TRPV1 receptor modulation was evaluated 21 days after chronic constriction injury (CCI) of the sciatic nerve in male Wistar rats. Microinjection of a bidirectional neurotracer in the PrL cortex showed connections with the lateral division of the mediodorsal thalamic nucleus (MDL), central division of the mediodorsal thalamic nucleus (MDC), centrolateral thalamic nucleus (CL), ventromedial thalamic nucleus (VM), and the paracentral thalamic nucleus (PC). In detail, AM251, a CB1 receptor antagonist (at 50, 100 and 200 pmol) microinjections intra-PrL cortex decreased the MWT. Administrations of 6-iodonordihydrocapsaicin (6-I-CPS), a transient receptor potential vanilloid type 1 (TRPV1) antagonist, at 3 nmol and the endocannabinoid anandamide (AEA) at 50 and 100 pmol increased the MWT. AEA at 200 pmol injected in the PrL cortex decreased the MWT, and this hyperalgesic effect was blocked by 6-I-CPS at 3 nmol. The AEA (at 100 pmol) anti-allodynic effect was attenuated by AM251 (at 5 pmol). The TRPV1 selective agonist N-oleoyldopamine (OLDA) at 10 μM decreased the MWT. The blockade of the NMDA receptor with LY235959 (at 8 nmol) and 6-I-CPS (at 3 nmol) reversed the OLDA (at 10 μM) hyperalgesic effect. These findings showed that the PrL cortex sends pathways to thalamic nuclei that can mediate the nociception. We also suggest that the PrL cortex is involved in the potentiation and maintenance of mechanical allodynia by NMDA and TRPV1 receptor activation and that attenuation of this allodynia depends on CB1 receptor activation during NP.